217 related articles for article (PubMed ID: 27456457)
1. Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer.
Liu HY; Yu X; Liu H; Wu D; She JX
Sci Rep; 2016 Jul; 6():30346. PubMed ID: 27456457
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
3. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
4. Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition.
Liu X; Gao R; Dong Y; Gao L; Zhao Y; Zhao L; Zhao X; Zhang H
BMC Cancer; 2010 Aug; 10():418. PubMed ID: 20698994
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression.
Pi F; Binzel DW; Lee TJ; Li Z; Sun M; Rychahou P; Li H; Haque F; Wang S; Croce CM; Guo B; Evers BM; Guo P
Nat Nanotechnol; 2018 Jan; 13(1):82-89. PubMed ID: 29230043
[TBL] [Abstract][Full Text] [Related]
6. Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein.
Shao Y; Liu Y; Shao C; Hu J; Li X; Li F; Zhang L; Zhao D; Sun L; Zhao X; Kopecko DJ; Kalvakolanu DV; Li Y; Xu DQ
Cancer Gene Ther; 2010 Dec; 17(12):844-54. PubMed ID: 20706288
[TBL] [Abstract][Full Text] [Related]
7. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
8. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
9. Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.
Ni X; Zhang Y; Zennami K; Castanares M; Mukherjee A; Raval RR; Zhou H; DeWeese TL; Lupold SE
Mol Cancer Ther; 2015 Dec; 14(12):2797-804. PubMed ID: 26438155
[TBL] [Abstract][Full Text] [Related]
10. Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Okamoto K; Okamoto I; Hatashita E; Kuwata K; Yamaguchi H; Kita A; Yamanaka K; Ono M; Nakagawa K
Mol Cancer Ther; 2012 Jan; 11(1):204-13. PubMed ID: 22075159
[TBL] [Abstract][Full Text] [Related]
11. Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on melanoma subcutaneous xenografts and lung metastases.
Kedinger V; Meulle A; Zounib O; Bonnet ME; Gossart JB; Benoit E; Messmer M; Shankaranarayanan P; Behr JP; Erbacher P; Bolcato-Bellemin AL
BMC Cancer; 2013 Jul; 13():338. PubMed ID: 23835136
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
Bae YJ; Yoon YI; Yoon TJ; Lee HJ
Korean J Radiol; 2016; 17(4):497-508. PubMed ID: 27390541
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
14. A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo.
Diao Y; Liu J; Ma Y; Su M; Zhang H; Hao X
Cancer Biol Ther; 2016 May; 17(5):498-506. PubMed ID: 26954374
[TBL] [Abstract][Full Text] [Related]
15. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
Dassie JP; Liu XY; Thomas GS; Whitaker RM; Thiel KW; Stockdale KR; Meyerholz DK; McCaffrey AP; McNamara JO; Giangrande PH
Nat Biotechnol; 2009 Sep; 27(9):839-49. PubMed ID: 19701187
[TBL] [Abstract][Full Text] [Related]
16. Plasmid-based Survivin shRNA and GRIM-19 carried by attenuated Salmonella suppresses tumor cell growth.
Liu YB; Zhang L; Guo YX; Gao LF; Liu XC; Zhao LJ; Guo BF; Zhao LJ; Zhao XJ; Xu DQ
Asian J Androl; 2012 Jul; 14(4):536-45. PubMed ID: 22580637
[TBL] [Abstract][Full Text] [Related]
17. A tumor-targeting cRGD-EGFR siRNA conjugate and its anti-tumor effect on glioblastoma in vitro and in vivo.
He S; Cen B; Liao L; Wang Z; Qin Y; Wu Z; Liao W; Zhang Z; Ji A
Drug Deliv; 2017 Nov; 24(1):471-481. PubMed ID: 28181832
[TBL] [Abstract][Full Text] [Related]
18. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.
Ni X; Zhang Y; Ribas J; Chowdhury WH; Castanares M; Zhang Z; Laiho M; DeWeese TL; Lupold SE
J Clin Invest; 2011 Jun; 121(6):2383-90. PubMed ID: 21555850
[TBL] [Abstract][Full Text] [Related]
19. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
